Sathish Vemula

pharmaceutical warning letters 483s news new guidelines guidance fda warning letter 483's non compliance reports regulatory gmp audit findings regulations newsletter fda news uptoday new guidance new mapp release audit analytical updates data integrity eu non compliance reports hplc error laboratory oos investigating aberrant potency values in pharma an aberrant investigation - introduction - roles & responsibilities- reaso sample preparation techniques of solid dosage form hplc or gc chromatography - apextrack integration regulations of july 2014 audit observations pharma noc regulation of the month pharma june 2014 chromatography waters pharmaceutical industry guidelines audit news uptoday new guidelines audit findings guest o december 2014 21 cfr 211.160 21 cfr 211.22 detecting and preventing issues 21 cfr 211.192 batch record review investigations chromatography data system (cds) in pharma 21 cfr 211.67 new 21 cfr 211.100; gmp; pharmaceutical news 21 cfr 211.165 who noc ema non compliance reports 21 cfr 211.42 buildings and facilities findings excipients unit operations processing problems introduction tablet manufacturing process all about tablets (pharma) solid dosage processing india - vetprom ad bulgaria - scm pharma limited uk guest of the month dr. m damodharan - vice pre 483 pharma septemer 2014 news october 2014 summary glp quality control